Capricor Therapeutics (CAPR) Misses Q1 EPS by 2c, Slight Miss on Revenues

Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of ($0.17), $0.02 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $880.81 thousand versus the consensus estimate of $900 thousand.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Morgan Stanley Starts Adani Enterprises Ltd. (ADE:IN) at Overweight
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance